Adjuvant chemotherapy for resected early-stage non-small cell lung cancer

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 3, 2015, Pages

  Burdett, Sarah ^a   Pignon, Jean Pierre ^b   Tierney, Jayne ^a   Tribodet, Helene ^b   Stewart, Lesley ^c   Le Pechoux, Cecile ^b   Aupérin, Anne ^b   Le Chevalier, Thierry ^b   Stephens, Richard J ^a   Arriagada, Rodrigo ^d   Higgins, Julian P T ^e   Johnson, David H ^f   Van Meerbeeck, Jan ^g   Parmar, Mahesh K B ^a   Souhami, Robert L ^h   Bergman, Bengt ⁱ   Douillard, Jean Yves ^j   Dunant, Ariane ^b   Endo, Chiaki ^k   Girling, David ^a   Kato, Harubumi ^l   Keller, Steven M ^m   Kimura, Hideki ⁿ   Knuuttila, Aija ^o   Kodama, Ken ^p   Komaki, Ritsuko ^q   Kris, Mark G ^r   Lad, Thomas ^s   Mineo, Tommaso ^t   Piantadosi, Steven ^u   Rosell, Rafael ^v   Scagliotti, Giorgio ^w   Seymour, Lesley K ^x   Shepherd, Frances A ^y   Sylvester, Richard ^z   Tada, Hirohito ^aa   Tanaka, Fumihiro ^ab   Torri, Valter ^ac   Waller, David ^ad   Liang, Ying ^ae   more..

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF YORK   (United Kingdom)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

^j Department of Medical Oncology Integrated Centers of Oncology R Gauducheau   (France)

^k TOHOKU UNIVERSITY   (Japan)

^l TOKYO MEDICAL UNIVERSITY   (Japan)

^m MONTEFIORE MEDICAL CENTER   (United States)

ⁿ CHIBA CANCER CENTER   (Japan)

^o HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^p OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^q UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^r MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^s Jr Hospital of Cook County   (United States)

^t TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^u CEDARS SINAI MEDICAL CENTER   (United States)

^v HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^w SAN LUIGI GONZAGA HOSPITAL   (Italy)

^x QUEEN S UNIVERSITY   (Canada)

^y PRINCESS MARGARET HOSPITAL   (Canada)

^z EORTC DATA CENTER   (Belgium)

^aa Saiseikai Imperial Gift Foundation Inc Saiseikai Suita Hospital   (Japan)

^ab UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^ac MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^ad GLENFIELD HOSPITAL   (United Kingdom)

^ae SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; TEGAFUR; URACIL; VINCA ALKALOID; VINORELBINE TARTRATE;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; AGE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELLS BY BODY ANATOMY; CHEMORADIOTHERAPY; CLINICAL OUTCOME; COMPARATIVE STUDY; EVIDENCE BASED MEDICINE; FUNCTIONAL STATUS; HISTOPATHOLOGY; HUMAN; LUNG RESECTION; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; SEX; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR BURDEN;

EID: 84942799847     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011430     Document Type: Review

References (92)

1. Kimura H, Yamaguchi Y, Fujisawa T, Baba M, Shiba M. A randomized controlled study of postoperative adjuvant chemoimmunotherapy of resected non-small cell lung cancer with IL2 and LAK cells. Lung Cancer 1991;7(Suppl):113.
2. Ohta M, Tsuchiya R, Shimoyama M, Sawamura K, Mori T, Miyazawa N, et al. Adjuvant chemotherapy for completely resected stage III non-small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery 1993;106:703-8.
3. Mineo TC, Ambrogi V, Corsaro V, Roselli M. Postoperative adjuvant therapy for stage IB non-small cell lung cancer. European Journal of Cardio-Thoracic Surgery 2001;20(2):378-84.
4. Park JH, Lee C-T, Lee HW, Baek HJ, Zo JI, Shim YM. Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer. European Journal of Cardio-Thoracic Surgery 2005;27:1086-91.
5. Park JH. Postoperative adjuvant therapy for stage IIIA non-small cell lung cancer. Journal of Thoracic Oncology 2007;2(8 Suppl 4):S651.
6. Scagliotti GV, Fossati R, Torri V, Crinò L, Giaccone G, Silvano G, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIa non-small cell lung cancer. Journal of the National Cancer Institute 2003;95(19):1453-61.
7. Arriagada R, Dunant A, Pignon J-P, Bergman B, Chabowski M, Grunenwald D, et al. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. Journal of Clinical Oncology 2010;28:35-42.
8. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. New England Journal of Medicine 2004;350:351-60.
9. Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MKB, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. European Journal of Cardio-Thoracic Surgery 2004;26:173-82.
10. Tada H, Tsuchiya R, Ichinose Y, Koike T, Nishizawa N, Nagai K, et al. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG 9304). Lung Cancer 2004;43:167-73.
11. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncology 2006;7:719-27.
12. Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, et al. Randomised phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage Ib and II non-small cell lung cancer: Updated survival analysis of JBR-10. Journal of Clinical Oncology 2010;28:29-34.
13. Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs observation in resected non-small cell lung cancer. New England Journal of Medicine 2005;352:2589-97.
14. Arriagada R, Dunant A, Pignon J-P, Bergman B, Chabowski M, Grunenwald D, et al. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. Journal of Clinical Oncology 2010;28:35-42.
15. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. New England Journal of Medicine 2004;350:351-60.
16. Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MKB, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. European Journal of Cardio-Thoracic Surgery 2004;26:173-82.
17. Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. Journal of Clinical Oncology 2008;26(31):5043-51.
18. Feld R, Rubinstein L, Thomas PA. Adjuvant chemotherapy with cyclophosphamide, doxorubicin and cisplatin in patients with completely resected stage I non-small-cell lung cancer. Journal of the National Cancer Institute 1993;85(4):299-306.
19. Niiranen A, Niitamo-Korhonen S, Kouri M, Assendelft A, Mattson K, Pyrhönen S. Adjuvant chemotherapy after radical surgery for non-small cell lung cancer: A randomized study. Journal of Clinical Oncology 1992;10(12):1927-32.
20. Figlin RA, Piantodosi S. A phase 3 randomized trial of immediate combination chemotherapy vs delayed combination chemotherapy in patients with completely resected stage II and III non-small cell carcinoma of the lung. Chest 1994;106(Suppl 6):310S-2S.
21. Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MKB, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. European Journal of Cardio-Thoracic Surgery 2004;26:173-82.
22. Study Group for Adjuvant Chemotherapy for Lung Cancer. A randomised controlled trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (in Japanese). Hai-gan 1992;32:481-6.
23. Sawamura K, Mori T, Doi O, Yasumitsu T, Kawahara O, Kuwabara M, et al. A prospective randomized controlled study of the postoperative adjuvant therapy for non-small cell lung cancer. Lung Cancer 1988;4:A166.
24. Study Group for Adjuvant Chemotherapy for Lung Cancer. A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). European Journal of Surgical Oncology 1995;21(1):69-77.
25. Teramatsu T, Society of adjuvant chemotherapy for lung cancer surgery in West Japan. Assessment of postoperative adjuvant chemotherapy on non-small cell lung cancer (abstract). Lung Cancer 1991;7(Suppl):124.
26. Wada H, Hitomi S, Takashi T, West Japan Study Group for Lung Cancer Surgery. Adjuvant chemotherapy after complete resection in non-small cell lung cancer (full publication). Journal of Clinical Oncology 1996;14:1048-54.
27. Wada H, Miyahara R, Tanaka F, Hitomi S, West Japan Study Group for Lung Cancer Surgery. Post-operative adjuvant chemotherapy with PVM (cisplatin + vindesine + mitomycin c) and UFT (uracil and tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomised clinical trial. European Journal of Cardio-Thoracic Surgery 1999;15:438-43.
28. Xu G, Rong T, Lin P. Adjuvant chemotherapy following radical surgery for non-small cell lung cancer: a randomized study. Zhonghua Zhong Liu Za Zhi 1998;20(3):228-30.
29. Imaizumi M. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer 2005;49:85-94.
30. Nakagawa K, Tada H, Akash iA, Yasumitsu T, Iuchi K, Taki T, et al. Randomised study of adjuvant chemotherapy for completely resected p stage I-IIIa non-small cell lung cancer. British Journal of Cancer 2006;95:817-21.
31. Sawamura K, Mori T, Doi O, Yasumitsu T, Kuwahara O, Kuwabara M, et al. A prospective randomized controlled study of the postoperative adjuvant therapy for non-small cell lung cancer. Lung Cancer 1988;4:A166.
32. Sawamura K, Mori T, Doi O, Yasumitsu T, Kuwahara O, Kuwabara M, et al. A prospective randomized controlled study of the postoperative adjuvant therapy for non-small cell lung cancer. Lung Cancer 1988;4:A166.
33. Wada H, Hitomi S, Takashi T,: West Japan Study Group for Lung Cancer Surgery. Adjuvant chemotherapy after complete resection in non-small cell lung cancer. Journal of Clinical Oncology 1996;14:1048-54.
34. Nakagawa M, Tanaka F, Tsubota N, Ohta M, Takao M, Wada H. A randomised phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG) - the 4th study. Annals of Oncology 2005;16:75-80.
35. Endo C, Saitoi Y, Iwanawi H, Tsushima T, Imai T, Kawamura M, et al. A randomized trial of postoperative UFT in p stage I, II non-small cell lung cancer: North-East Japan Study Group for Lung Cancer Surgery. Lung Cancer 2003;40:181-6.
36. Nakagawa K, Tada H, Akash iA, Yasumitsu T, Iuchi K, Taki T, et al. Randomised study of adjuvant chemotherapy for completely resected p stage I-IIIa non-small cell lung cancer. British Journal of Cancer 2006;95:817-21.
37. Imaizumi M. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer. Lung Cancer 2005;49:85-94.
38. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al. A randomised trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. New England Journal of Medicine 2004;350(17):1713-21.
39. Pisters KMW, Kris MG, Gralla RT, Hilaris B, McCormack PM, Bains MS. Randomized trial comparing post-operative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer. Journal of Surgical Oncology 1994;56:236-241.
40. Dautzenberg B, Chastang C, Arriagada R, Le Chevalier T, Belpomme D, Hurdebourcq M, et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected non-small cell lung cancer. Cancer 1995;76:779-86.
41. EORTC Lung Cancer Cooperative Group. Phase III randomized trial of adjuvant radiotherapy vs radiotherapy plus chemotherapy with DDP/VDS vs no adjuvant therapy in patients with completely resected non-small cell lung cancer.
42. MD Anderson Cancer Centre. Phase III randomized comparison of chest irradiation vs combination chemotherapy with cyclophosphamide/etoposide/cisplatine (CEP) followed by chest irradiation in patients with partially resected stage II/III limited non small cell lung cancer.
43. Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brookes BJ, et al. Postoperative adjuvant therapy in patients with stage II or IIIa non-small cell lung cancer. New England Journal of Medicine 2000;343:1217-22.
44. Scagliotti GV, Fossati R, Torri V, Crinò L, Giaccone G, Silvano G, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIa non-small cell lung cancer. Journal of the National Cancer Institute 2003;95(19):1453-61.
45. Arriagada R, Dunant A, Pignon J-P, Bergman B, Chabowski M, Grunenwald D, et al. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. Journal of Clinical Oncology 2010;28:35-42.
46. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. New England Journal of Medicine 2004;350:351-60.
47. Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MKB, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. European Journal of Cardio-Thoracic Surgery 2004;26:173-82.
48. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncology 2006;7:719-27.
49. Arriagada R, Dunant A, Pignon J-P, Bergman B, Chabowski M, Grunenwald D, et al. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. Journal of Clinical Oncology 2010;28:35-42.
50. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. New England Journal of Medicine 2004;350:351-60.
51. Lad T. The comparison of CAP chemotherapy and radiotherapy to radiotherapy alone for resected lung cancer with positive margin or involved highest sampled paratracael node (stage IIIa). Chest 1994;106(6):303S.
52. Lad T, Rubinstein L, Sadeghi A. The benefit of adjuvant treatment for resected locally advanced non-small cell lung cancer. Journal of Clinical Oncology 1988;6:9-17.
53. Niiranen, Kouri M, Pyrhonen S, Mattson K. Postsurgical radiotherapy versus postsurgical radiotherapy plus chemotherapy for non-small cell lung cancer.
54. Sawamura K, Mori T, Doi O, Yasumitsu T, Kawahara O, Kuwabara M, et al. A prospective randomized controlled study of the postoperative adjuvant therapy for non-small cell lung cancer. Lung Cancer 1988;4:A166.
55. Ayoub J, Vigneault E, Hanley J, Duranceau A, Robidoux A, Pagé A, et al. The Montreal multicenter trial in operable non-small cell lung cancer (NSCLC): A multivariate analysis of the predictors of relapse. Proceedings of the American Society of Clinical Oncology 1991;10:247.
56. Clerici M, Barni S, Cantaluppi G, et al. Adjuvant chemotherapy in non-small cell lung cancer: a randomised trial. European Journal of Cancer 1991;27(Suppl 2):S173.
57. Ichinose Y, Hara N, Ohta M, Motohiro A, Kuda T, Aso H. Postoperative adjuvant chemotherapy in non-small cell lung cancer: Prognostic value of DNA ploidy and postrecurrent survival. Journal of Surgical Oncology 1991;46:15-20.
58. Kim S-W, Suh CS, Lee G-W, Ryu M-H, Lee SD, Kim WS, et al. The number of tumor (+) N2 nodes as a prognostic factor in the patients with N2 disease non-small cell lung cancer after curative resection and postoperative thoracic radiotherapy. Lung Cancer 2003;41(Supplement 2):S152.
59. Ueda H, Sakada T, Kuwahara M, Motohiro A. A small randomized phase III single-center trial on postoperative UFT administration in patients with completely resected non-small cell lung cancer. Anti-Cancer Drugs 2004;15(1):29-33.
60. Wang S, Ou W, Sun H, Yang HX, Fang Q. Adjuvant chemotherapy in completely resected stage III-N2 non-small cell lung cancer. Proceedings of the American Society of Clinical Oncology 2009;27:A7563.
61. Wolf M, Müller H, Seifart U, Friedel G, Hruska D, Serke M, et al. Randomized phase III trial of adjuvant radiotherapy versus adjuvant chemotherapy followed by radiotherapy in patients with N2 positive non-small cell lung cancer (NSCLC). Proceedings of the American Society of Clinical Oncology 2001;20:311a.
62. Wu Y, Yang X, Chen G, Zhong W, Ben X-S, Gu L, et al. Adjuvant docetaxel plus carboplatin compared with surgery only in patients with completely resected stage IB-IIIA non-small cell lung cancer: final results of CSLC201/TAX210 with Chinese Society of Lung Cancer. Journal of Thoracic Oncology 2009;4(9):S583-S584.
63. Zarogoulidis K, Filippou K, Antonio C, Papagiannis A, Hatziapostolou P, Tsiagga P, et al. The impact of adjuvant chemotherapy on the survival of postoperative stage IIIa NSCLC patients. Proceedings of the 2nd International Congress on Lung Cancer. Crete. 1996:PO35.
64. Felip E, Rosell R, Maestre JA, Rodriguez-Paniagua JM, Moran T, Astudillo J, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. Journal of Clinical Oncology 2010;28(19):3138-45.
65. Zheng S, Jiang S, Li H. Adjuvant chemotherapy following radical surgery for non-small cell lung cancer: a randomised study on 70 patients. Journal of Thoracic Oncology 2011;6(6 Suppl 2):S866.
66. CALGB 30506: Phase III randomised study of adjuvant chemotherapy versus observation in patients with early stage non-small cell lung cancer. Ongoing study March 2009.
67. American Cancer Society. Cancer Facts and Figures 2007. www.cancer.org/acs/groups/content/@nho/documents/document/caff2007pwsecuredpdf.pdf (accessed in December 2009) 2007.
68. Arriagada R, Dunant A, Pignon J-P, Bergman B, Chabowski M, Grunenwald D, et al. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. Journal of Clinical Oncology 2010;28(1):35-42.
69. Berghmans T, Paesmans M, Meert AP, Mascaux C, Lothaire P, Lafitte JJ, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: Results of a meta-analysis of the literature. Lung Cancer 2005;49(1):13-23.
70. Bria E, Gralla RJ, Raftopoulous H, Ferretti G, Felici A, Nistico C. Does adjuvant chemotherapy improve survival in non-small cell lung cancer (NSCLC)? A pooled analysis of 6494 patients in 12 studies, examining survival and magnitude of benefit. Journal of Clinical Oncology 2005;23(16S):7140.
71. Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, et al. Randomised phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage Ib and II non-small cell lung cancer: Updated survival analysis of JBR-10. Journal of Clinical Oncology 2010;28(1):29-34.
72. Datta D, Lahiri B. Preoperative evaluation of patients undergoing lung resection surgery. Chest 2003;123(6):2096-103.
73. Fisher DJ, Copas AJ, Tierney JF, Parmar MKB. A critical review of methods for the assessment of patient-level interactions in individual patient data (IPD) meta-analysis of randomised trials, and guidance for practitioners. Journal of Clinical Epidemiology 2011;64(9):949-967.
74. Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, Imaizumi M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small cell lung cancer. Journal of Clinical Oncology 2005;23(22):4999-5006.
75. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Handbook for Systematic Reviews of Interventions - Version 5.0.1 (updated in September 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
76. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: Reappraisal with a meta-analysis of randomised controlled trials. Journal of Clinical Oncology 2004;22(19):3860-7.
77. International Association for the Study of Lung Cancer. Staging Manual in Thoracic Oncology. 1st Edition. Orange Park, FL, USA: Editorial Rx Press, 2009.
78. Lefebvre C, Clarke MJ. Identifying randomised trials. In: Egger M, Smith GD, Altman DG editor(s). Systematic reviews in healthcare. 2nd Edition. London: BMJ Publishing Group, 2001:69-87.
79. Lefebvre C, Manheimer E, Glanville J, Cochrane Information Retrieval Methods Group. Searching for studies. In: Higgins JPT, Green S, Editors. Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:95-150.
80. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311(7010):899-909.
81. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD002139]
82. Parkin DM, Bray F, Ferlay J, Pisani Paola. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2005;55(2):74-108.
83. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE Collaborative Group. Journal of Clinical Oncology 2008;26(21):3552-9.
84. Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. Journal of Clinical Oncology 2007;25(34):5506-18.
85. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998;352(9124):257-63.
86. PORT Meta-analysis Trialists Group. Postoperative radiotherapy for non-small cell lung cancer. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002142.pub2]
87. The Cochrane Collaboration. Review Manager (RevMan). Computer Program. 5.3.5 Copenhagen: the Nordic Cochrane Centre. The Cochrane Collaboration, 2014.
88. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Controlled Clinical Trials 1996;17(4):343-6.
89. Sedrakyan A, van Der Meulen J, O'Byrne K, Prendiville J, Hill J, Treasure T. Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. Journal of Thoracic and Cardiovascular Surgery 2004;128(3):414-9.
90. Sekine I, Yamamoto N, Nisho K, Saijo N. Emerging ethnic differences in lung cancer therapy. British Journal of Cancer 2008;99(11):1757-62.
91. Toyooka S, Hotta K, Nakamura H, Nakata M, Tada H, Yamashita M, et al. A multicenter, phase III study of carboplatin/paclitaxel, versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): planned interim analyses. Proceedings of the American Society of Clinical Oncology 2009;27(15):A7560.
92. Non-Small Cell Lung Cancer Collaborative Group. Adjuvant chemotherapy, with or without postopertative radiotherapy, in operable non-small cell lung cancer: two meta-analyses of individual patient data. Lancet 2010;375(9722):1267-77.